(NASDAQ: NBTX) Nanobiotix Sa's forecast annual revenue growth rate of 79.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 111.12%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.76%.
Nanobiotix Sa's revenue in 2026 is $11,950,588.On average, 7 Wall Street analysts forecast NBTX's revenue for 2026 to be $2,525,961,514, with the lowest NBTX revenue forecast at $1,181,798,440, and the highest NBTX revenue forecast at $5,923,463,199. On average, 7 Wall Street analysts forecast NBTX's revenue for 2027 to be $2,513,950,583, with the lowest NBTX revenue forecast at $472,719,376, and the highest NBTX revenue forecast at $4,462,133,251.
In 2028, NBTX is forecast to generate $3,557,840,380 in revenue, with the lowest revenue forecast at $197,963,298 and the highest revenue forecast at $7,664,807,022.